There is good news for diabetes researchers. More than €2.5m (£2.1m) in funding is being offered by German pharmaceutical firm Boehringer Ingelheim (BI) and the European Foundation for the Study of Diabetes (EFSD) for research projects targeting specific areas of interest.
As part of a new funding and research partnership between BI and the EFSD, grants of up to €100,000 are available for basic research projects lasting up to two years, rising to €400,000 for clinical research studies lasting three years or less.
Projects must focus on either the regulations of secretion and/or function of non-insulin peptides from the endocrine pancreas (basic research), or mechanisms relating renal dysfunction to cardiovascular disease in type 2 diabetes (clinical and translational studies).
Applications are open to single non-profit institutions or groups of institutions in Europe until April 1, and will be subject to a scientific review by a specialised and independent committee.
Professor Klaus Dugin, corporate senior vice president for medicine at BI, said: “We are delighted to partner with the EFSD on this initiative and hope the grant encourages and supports new research in the field of diabetes.
“Diabetes affects more than 371 million people worldwide and diabetes remains undiagnosed in up to 50 per cent of cases.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…